Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 0.61 |
| ▸ | KMO | O15229 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9934410 | 1.00 | RECQL (0.61) | RECQLKMOCYP1A2ADRA2APOLB | |
| SCHEMBL31429458 | 0.84 | KMO (0.65) | RECQLKMOCYP1A2ADRA2APOLB | |
| SCHEMBL14578726 | 0.84 | KMO (0.65) | RECQLKMOCYP1A2ADRA2APOLB | |
| SCHEMBL4951648 | 0.81 | KMO (0.61) | RECQLKMOCYP1A2ADRA2APOLB | |
| SCHEMBL7331551 | 0.81 | RECQL (0.69) | RECQLKMOCYP1A2ADRA2APOLB | |
| SCHEMBL5365409 | 0.80 | KMO (0.59) | RECQLKMOCYP1A2ADRA2APOLB | |
| SCHEMBL9934408 | 0.79 | RECQL (0.61) | RECQLKMOCYP1A2ADRA2APOLB | |
| SCHEMBL13217 | 0.79 | RECQL (0.61) | RECQLKMOCYP1A2ADRA2APOLB | |
| SCHEMBL3076519 | 0.79 | RECQL (0.61) | RECQLKMOCYP1A2ADRA2APOLB | |
| SCHEMBL29520910 | 0.79 | RECQL (0.61) | RECQLKMOCYP1A2ADRA2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568948-A1 | COMPOUNDS FOR TREATING CANCER | Genesis Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024059010-A1 | COMPOUNDS FOR TREATING CANCER | GENESIS THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11649255-B2 | Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same | 1ST Biotherapeutics, Inc. (KR) | 2023-05-16 | — | — | US | disclosed |
| US-20220098193-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME | 1ST Biotherapeutics, Inc. | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649255-B2 | Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same | IP6K1, HIPK1, IP6K3 | RECQL 1162/4885KMO 1689/4885CYP1A2 1840/4885 |
| US-20220098193-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME | IP6K1, HIPK1, IP6K3 | RECQL 1162/4885KMO 1689/4885CYP1A2 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.